The FDA has approved Vykat XR (diazoxide choline) for the treatment of hyperphagia in adults and pediatric patients 4 years ...
Approval of Vykat XR marks the first treatment indicated for hyperphagia in patients with Prader-Willi syndrome.
The United States Food and Drug Administration (US FDA) has approved VYKATâ„¢ XR, a significant milestone as the first approved treatment for hyperphagia in Prader-Willi syndrome (PWS).
Soleno Therapeutics ($SLNO) stock skyrocketed up over 42% this past week on news that it has achieved a significant milestone ...
Soleno Therapeutics has won US Food and Drug Administration (FDA) approval for diazoxide choline – which will be branded as ...
Under the new collaboration, OpenFold will produce a fine-tuned version of its model that’s trained on AbbVie and Johnson & ...
Since 2000, when the FDA approved recombinant human growth hormone (rhGH) for those with the rare genetic disorder ...
The FDA Wednesday approved the first drug to treat people with Prader-Willi syndrome, a rare genetic disease that causes an ...
Vykat XR will be available in April to treat the intense hunger that is a hallmark of the rare genetic disease Prader-Willi ...
The US Food and Drug Administration (FDA) has approved Soleno Therapeutics’ Vykat XR (diazoxide choline) extended-release ...
Federal regulators are clearing a first-of-its-kind treatment for symptoms of a rare neurodevelopmental disorder that is ...
(Reuters) -The U.S. Food and Drug Administration on Wednesday approved Soleno Therapeutics' drug to treat a rare genetic ...